
1. malar j. 2018 jul 16;17(1):267. doi: 10.1186/s12936-018-2411-5.

chloroquine resistance associated multi-copy pvcrt-o gene plasmodium
vivax malaria brazilian amazon.

silva sr(1)(2), almeida acg(1)(2), da silva gav(1), ramasawmy r(1)(2), lopes
scp(1)(3), siqueira am(1)(4), costa gl(5), sousa tn(5), vieira jlf(6), lacerda
mvg(1)(3), monteiro wm(1)(2), de melo gc(7)(8).

author information: 
(1)fundação de medicina tropical dr. heitor vieira dourado, manaus, amazonas,
69040-000, brazil.
(2)universidade estado amazonas (uea), manaus, amazonas, 69040-000, brazil.
(3)instituto leônidas & maria deane (ilmd), fiocruz, manaus, amazonas, 69057-070,
brazil.
(4)instituto nacional de infectologia, evandro chagas, fiocruz, rio de janeiro,
21040-360, brazil.
(5)centro de pesquisas rené rachou, fiocruz, belo horizonte, minas gerais,
30190-002, brazil.
(6)universidade federal pará, belém, pará, 66010-010, brazil.
(7)fundação de medicina tropical dr. heitor vieira dourado, manaus, amazonas,
69040-000, brazil. cardosogisely@gmail.com.
(8)universidade estado amazonas (uea), manaus, amazonas, 69040-000, brazil.
cardosogisely@gmail.com.

background: resistance plasmodium vivax chloroquine become an
obstacle control strategies based use anti-malarials. current
study investigated association p. vivax cq-resistance vivo with
copy number variation mutations promoter region pvcrt-o pvmdr1 
genes.
methods: study included patients p. vivax received supervised
treatment chloroquine primaquine. recurrences actively recorded
during period.
results: among 60 patients p. vivax, 25 cq-resistant 35
cq-susceptible. frequency 7.1% multi-copy pvcrt-o observed in
cq-susceptible samples 7.7% cq-resistant d0 (p > 0.05) 33.3% in
cq-resistant dr (p < 0.05). pvmdr1, 10.7% cq-susceptible samples
presented multiple copies compared 11.1% cq-resistant d0 0.0% in
cq-resistant dr (p > 0.05). deletion 19 bp found 11/23 (47.6%) 
the patients cq-susceptible p. vivax 3/10 (23.1%) samples in
cqrpv d0. day dr, 55.5% samples cqrpv 19 bp deletion.
for pvmdr-1 gene, variation analysed gene compared p.
vivax reference sal-1.
conclusions: first study 42-day clinical follow-up evaluate 
the variation number copies polymorphisms promoter region of
the pvcrt-o pvmdr1 genes relation treatment outcomes. significantly
higher frequency multi-copy pvcrt-o found cqrpv samples dr compared 
to cq-susceptible, indicating parasite selection genotype cq
treatment association cq-resistance vivo.

doi: 10.1186/s12936-018-2411-5 
pmcid: pmc6048775
pmid: 30012145  [indexed medline]

